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Different Hepatitis B Virus Genotypes Are Associated
With Different Mutations in the Core Promoter and Precore
Regions During Hepatitis B e Antigen Seroconversion
HENRY L. Y. CHAN, MUNIRA HUSSAIN, AND ANNA S. F. LOK
Mutations in the core promoter and precore regions are
frequently found in hepatitis B e antigen (HBeAg)-negative
patients, but precore stop codon mutation is restricted to
hepatitis B virus (HBV) genotypes that have T at nucleotide
1858. The aims of this study were to determine the role of
core promoter and/or precore mutations in HBeAg serocon-
version and their impact on the subsequent course of liver
disease, and to determine if core promoter mutations are
more frequently selected in patients with HBV genotypes
that preclude the development of precore stop codon
mutation. Serial sera from 45 patients with chronic HBV
infection were polymerase chain reaction (PCR)-amplified,
and the HBV core promoter and precore regions were
sequenced. Ninety-two percent of patients had core pro-
moter or precore mutations after HBeAg seroconversion:
42% had core promoter changes only, 38% had precore stop
codon mutations only, and 12% had changes in both
regions. Seventy-three percent of the patients had persis-
tently normal aminotransferases, and only 8% had multiple
flares in aminotransferases after HBeAg seroconversion.
Core promoter changes were significantly more common in
patients infected with HBV who have C at nucleotide 1858
(91% vs. 27%; P F .01), while precore stop codon changes
were exclusively found in patients infected with HBV who
have T at nucleotide 1858 (87% vs. 0; P F .01). The vast
majority of our patients had core promoter and/or precore
mutations after HBeAg seroconversion. Nevertheless, most
patients had sustained remission of liver disease. Our data
suggest that core promoter changes are preferentially se-
lected in patients infected with HBV genotypes that pre-
clude the development of precore stop codon mutation.
(HEPATOLOGY 1999;29:976-984.)
Mutations in the precore region of the hepatitis B virus
(HBV) genome have been reported in many hepatitis B e
antigen (HBeAg)-negative patients with chronic HBV infec-
tion.1-7 The predominant mutation involves a G-to-A change
at nucleotide 1896 (A1896), which creates a premature stop
codon at codon 28 (Fig. 1). This mutation prevents the
translation of the precore protein and completely abolishes
the production of HBeAg. Longitudinal studies found that
A1896 emerges or is selected around the time of HBeAg
seroconversion.2,5-7 These findings suggest that A1896 plays
an important role in HBeAg clearance. However, not all
patients develop A1896 after HBeAg seroconversion; some
patients retain wild-type precore sequence, while others have
undetectable HBV DNA in serum (by polymerase chain
reaction [PCR] assay). It is now recognized that the occur-
rence of A1896 is restricted to HBV genotypes with T at
nucleotide 1858.4,8-10 A change from G to A at nucleotide
1896 increases the stability of the stem-loop structure of the
pregenome encapsidation sequence (e) when the opposite
nucleotide at 1858 is a T (T1858), but this change disrupts a
pre-existing C-G pair when the nucleotide at 1858 is a C
(C1858).4 The restriction of A1896 to specific HBV genotypes
accounts for its high prevalence in Asia and the Mediterra-
nean basin, where the predominant HBV genotypes (B, C, and
D) frequently have T1858, and its low prevalence in North
America and Europe, where the predominant HBV genotype
(A) almost always has C1858.9,10 In our previous studies of
Chinese patients from Hong Kong, we found that only 60% of
patients were infected with HBV genotypes that have T1858.4
Nevertheless, patients infected with HBV genotypes that have
C1858, which precludes the development of A1896, appeared
to clear HBeAg at rates similar to those infected with HBV
genotypes that have T1858.11
Recent studies reported that mutations in the core pro-
moter region can be found in many HBeAg-negative patients;
the most common mutations involve a two-nucleotide substi-
tution: A-T at nucleotide 1762 and G-A at nucleotide 1764
(TA) (Fig. 2).12-15 In some patients, the TA changes were not
associated with A1896, suggesting that mutations in the core
promoter region alone may play a role in HBeAg clearance.
This hypothesis is supported by in vitro observations that the
TA changes decrease transcription of precore mRNA and
secretion of HBeAg.16-20 However, TA changes have also been
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found in some HBeAg-positive patients, especially those with
chronic hepatitis.12,13 Thus, the role of core promoter muta-
tions in HBeAg clearance is unclear.
Most reports of core promoter mutations came from Japan.
There are very little data on the prevalence of core promoter
mutations in other parts of the world. It is not clear if the
prevalence of core promoter mutations differ in different
geographical regions and if the occurrence of these mutations
is restricted to specific HBV genotypes.
Initial studies reported that A1896 was predominantly
found in patients with fulminant hepatitis or chronic active
hepatitis, suggesting that the precore stop codon mutation
may be more pathogenic.2,3,21,22 Subsequent studies showed
that A1896 can also be found in asymptomatic carriers.23,24
Nevertheless, there remains lingering concerns that HBeAg
seroconversion associated with the development of A1896 is
less likely to result in remission of liver disease. Similarly,
early studies reported that core promoter mutations were
mainly found in patients with fulminant hepatitis or chronic
active hepatitis,12,13,15,25 but later studies showed that TA
changes were also found in asymptomatic carriers.12,14 Thus,
it is unclear if TA changes influence the severity or course of
liver disease after HBeAg seroconversion.
In this study, we analyzed serial HBV precore and core
promoter sequences in Chinese patients with chronic HBV
infection before and after HBeAg seroconversion to determine
whether: 1) core promoter and/or precore mutations were
detected in all patients after HBeAg seroconversion; 2) core
promoter mutations were more frequently selected in patients
with HBV genotypes that have C1858, which precludes the
development of A1896; and 3) the development of core
promoter and/or precore mutations was associated with
active liver disease after HBeAg seroconversion.
PATIENTS AND METHODS
Patients. Forty-five Chinese patients with chronic HBV infection
who were seen in the Hepatitis Clinic, Queen Mary Hospital, Hong
Kong, were studied. These patients were selected based on the
availability of two or more serum samples over a follow-up period of
at least 2 years. They included 27 (60%) males and 18 (40%)
females, aged 10 to 40 years (mean 6 SD: 25 6 7 years). All patients
were negative for hepatitis C and hepatitis D antibodies. All patients
were HBeAg-positive at presentation. Group I included 26 patients
with sustained HBeAg to HBe antibody (anti-HBe) seroconversion.
Group II included 19 controls who were persistently HBeAg-positive
during the follow-up period. These patients were further divided
into groups A (C1858) and B (T1858) based on the sequence at
nucleotide position 1858 in the precore region. The HBV S gene
sequence was determined in previous studies in 13 patients. Five
patients (patients 13, 15, 18, 21, and 40) were infected with HBV
genotype B, all of whom had T1858. Eight patients (patients 8, 10,
12, 38, 34, 35, 36, and 44) were infected with HBV genotype C; all
but 1 (patient 44) had C1858. Twenty-three (51%) patients, 14 in
group I and 9 in group II, received interferon alfa treatment for 3 to 6
months in two previously reported interferon trials,26,27 while the
remaining 22 patients (49%) never received interferon or other
antiviral treatment.
Materials. An aliquot of serum was collected at each clinic visit
(every 1 to 6 months) and stored at 270°C for HBV DNA assay. The
earliest and latest available serum samples of each patient were
analyzed. The interval between these samples ranged from 31 to 93
months (mean 6 SD: 63 6 20 months). In group I patients, one
serum sample must be available before and the other one after
HBeAg seroconversion. Additional interval samples were studied in
FIG. 1. The core promoter and precore sequences and the location of the TA change and A1896 (stop codon) mutation. The transcription initiation sites of
the precore messenger RNA and the pregenomic RNA are indicated by arrows. Transcription factor binding sites (Sp1 and TBP) are underlined.
HEPATOLOGY Vol. 29, No. 3, 1999 CHAN, HUSSAIN, AND LOK 977
patients who had changes in the core promoter and precore regions
to determine the timing of emergence of these mutants. The time of
emergence of these mutations was defined as the time when the
initial sample was collected if the mutation was detected in that
sample, and the midpoint between the last sample when the
mutation was absent and the first sample when the mutation was
detected if the mutation developed during follow-up. The initial
samples of all the 23 patients who received interferon were collected
before initiation of therapy.
Hepatitis Serology and HBV DNA Assay. Hepatitis B, C, and D virus
serological markers were tested using commercially available enzyme-
linked immunosorbent assay kits from Abbott Laboratories (North
Chicago, IL). HBV DNA was determined by a semiquantitative
dot-blot hybridization assay.27
PCR Amplification and Direct Sequencing. DNA was extracted by
incubating 100 µL serum with 50 µL buffer containing (final
concentration) 0.5 mg/mL proteinase K, 10 mmol/L Tris-HCl (pH
8.0), 20 mmol/L ethylenediaminetetraacetic acid, and 0.5% sodium
dodecyl sulfate at 50°C for 2 hours. The samples were extracted by
Qiaquick spin columns (Qiagen Inc., Chatsworth, CA) according to
the manufacturer’s instructions. The extracted DNA was eluted with
30 µL H2O.
First-round PCR was performed on 5 µL of DNA extract in a
50-µL reaction mix containing (final concentration) 10 mmol/L
Tris-HCl (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl2, 0.25 µmol/L
of each of the four deoxynucleotide triphosphates, 2.5 U Taq
polymerase (Perkin Elmer, Foster City, CA), and 0.6 mmol/L of each
of the external primers. The reaction was performed in a Personal
Cycler (Biometra Inc., Tampa, FL) for 36 cycles at 94°C for 1
minute, 56°C for 1 minute, and 72°C for 3 minutes, with a 7-minute
extension step at 72°C at the end. For the second-round PCR, 2 µL
of first-round PCR product was added to 48 µL of reaction mix with
the same composition as the first-round reaction, except that
internal primers were used. Five microliters of the second-round
PCR products was analyzed by electrophoresis in a 1% agarose gel
stained with ethidium bromide, and visualized with an ultraviolet
transilluminator.
External primers were P1 (58-TCGCATGGAGACCACCGTGA-
38, positions 1604-1623) and P2 (58-ATAGCTTGCCTGAGTGC-38,
positions 2076-2060); internal primers were P3 (58-CATAAGAG-
GACTCTTGGACT-38, positions 1653-1672) and P4 (58-GGAA-
AGAAGTCAGAAGGC-38, positions 1974-1957). All necessary pre-
cautions to prevent cross-contamination were observed, and negative
controls were included in each assay.
Amplified PCR products were purified by Qiaquick spin columns
(Qiagen Inc.) according to the manufacturer’s instructions. Purified
HBV DNA was directly sequenced by the DNA sequencing core
facility at the University of Michigan Medical Center using the
standard protocol for the Applied Biosystems DNA sequencer 373A
(Perkin Elmer Corp.) using primers P4 and P3.
Statistical Analyses. The two-tailed Student t test was used to
compare continuous variables, and the Fisher’s two-tailed exact test
was used to compare categorical data.
RESULTS
At presentation, patients who had sustained HBeAg serocon-
version (group I) were significantly older than those who
were persistently HBeAg-positive (group II), mean ages for
groups I and II patients being 29 6 5 years versus 21 6 7
FIG. 2. Patient 14, who had T1858 in the precore region and normal ALT levels during the first 3 years of follow-up. HBeAg seroconversion was preceded
by multiple flares in ALT and emergence of precore stop codon mutation (A1896). ALT levels normalized just before HBeAg seroconversion and remained
normal during the course of follow-up. Broken line, HBV DNA; straight line, ALT.
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years, respectively (P , .01) (Table 1). There was no
difference in sex distribution, percent of patients who re-
ceived interferon treatment, or duration of follow-up between
the two groups of patients.
Core Promoter and Precore Mutations in Relation to HBeAg
Seroconversion (Group I). Among the patients who had sus-
tained HBeAg seroconversion (group I), 11 (42%) had core
promoter, but only 2 (8%) had precore stop codon mutations
at presentation (Table 2). During follow-up, 3 (12%) patients
developed core promoter, while 11 (42%) developed precore
stop codon changes. Overall, 92% of the patients had core
promoter or precore mutations after HBeAg seroconversion:
42% had core promoter changes only, 38% had precore stop
codon mutations only, and 12% had changes in both regions.
Core promoter changes were significantly more common in
patients infected with HBV who have C1858 (91% vs. 27%;
P , .01), while precore stop codon changes were exclusively
found in patients infected with HBV who have T1858 (87%
vs. 0; P , .01).
Mutations in the core promoter region appeared earlier and
were detected in almost all (93%) patients during the
HBeAg-positive phase, while precore stop codon mutations
tended to appear around the time of HBeAg seroconversion.
The mean interval between the first detection of core pro-
moter mutations and HBeAg seroconversion was significantly
longer: 18 6 22 months (range, 258 to 124 months) than
the mean interval between the first detection of precore stop
codon mutation and HBeAg seroconversion: 2 6 16 months
(range, 218 to 135 months) (P , .05) (Table 3). Of the 3
patients who had both core promoter and precore mutations,
TA changes appeared 7 and 25 months before A1896 in 2
patients (patients 12 and 25) and simultaneously with A1896
in the third patient (patient 24).
Core Promoter and Precore Mutations in Patients Infected With
HBV Who Have C1858 (Groups IA and IIA). Among the patients
infected with HBV who have C1858, a significantly higher
percentage of patients who had sustained HBeAg seroconver-
sion (group IA) had core promoter changes compared with
those who were persistently HBeAg-positive (group IIA) in
both the initial (82% vs. 9%) as well as the last available
samples (91% vs. 36%; [P 5 .02]) (Table 2).
Nine of 11 (82%) group IA patients had core promoter
changes in the initial serum samples collected 4 to 59 months
before HBeAg seroconversion (Table 3). Another patient
(patient 6) developed core promotor changes during follow-
up, 24 months after HBeAg seroconversion. Only 1 (9%)
patient (patient 2) had no detectable core promoter change
up to 46 months after HBeAg seroconversion. In contrast, in
group IIA patients, only 1 of 11 (9%) had core promoter
changes in the initial serum sample (Table 4). Three patients
(patients 29, 30, 32) developed core promotor changes after
9, 17, and 74 months of follow-up. Seven patients had no core
promoter changes after a mean follow-up period of 63 6 18
months (range, 33-84 months).
All patients who had core promoter changes retained those
changes throughout the course of follow-up. Of the 14
patients who had core promoter changes, T1762 and A1764
(TA) were simultaneously detected in 10 patients (Tables 3
and 4). In the remaining 4 patients, 3 (patients 7, 9, 10) had
A1764 change only (AA) in the initial samples, 1 of whom
(patient 10) developed additional an T1762 change during
follow-up, while the other 2 still had an isolated A1764
change 9 and 75 months after HBeAg seroconversion. The
fourth patient (patient 29) evolved from wild-type core
promoter sequence (AG) in the initial sample to isolated
A1764 change (AA) after 74 months, with an additional
T1762 change (TA) 4 months later. None of our patients had
an isolated T1762 change.
None of the patients infected with HBV who have C1858
had a precore stop codon mutation (A1896) (Table 2).
However, 1 patient (patient 4) had a mutation of the precore
start codon.
Core Promoter and Precore Mutations in Patients Infected With
HBV Who Have T1858 (Groups IB and IIB). Among the patients
infected with HBV who have T1858, patients who had
sustained HBeAg seroconversion (group IB) had a signifi-
cantly higher prevalence of precore stop codon mutation than
those who were persistently HBeAg-positive (group IIB) in
the last available samples: 87% vs. 25% (P , .01), but this
difference was not evident in the initial samples: 13% vs. 0%
(NS) (Table 2). There was no difference in the prevalence of
core promoter changes in both the initial and the last
available samples between these two groups (Table 2).
Two (13%) of 15 patients (patients 20, 23) who had
sustained HBeAg seroconversion (group IB) had precore stop
codon mutation in the initial samples collected 8 and 10
months before HBeAg seroconversion (Table 3). Eleven
additional patients developed precore stop codon mutation
during follow-up; in 6 patients, A1896 was detected 6 to 18
months before HBeAg seroconversion, while in the other 5
patients, A1896 was first detected 1 to 35 months after HBeAg
seroconversion. Among the 13 patients with precore stop
codon mutations, 3 also had core promoter changes (patients
12, 24, and 25). In the remaining 2 patients who did not have
precore stop codon mutation, 1 (patient 21) developed a
21-bp deletion (nucleotides 1748-1768) in the core promoter
region, while the other patient (patient 16) had no detectable
change in both the core promoter and precore regions. None
of the patients who remained HBeAg-positive (group IIB) had
precore stop codon mutation in the initial samples; only 2
(patients 40, 45) developed A1896 during follow-up (Ta-
ble 4). None of the group IIB patients had core promoter
changes in any of the samples studied.
Effect of Interferon Treatment on the Development of Core
Promoter and Precore Mutations. Fourteen group I and 9 group
II patients received interferon therapy during the study
period. New mutations appeared in similar proportions of
















I 26 14/12 29 6 5 (13-37) yes 14 (54) 63 6 19 (31-92)
II 19 13/6 21 6 7 (10-40) no 9 (47) 62 6 20 (32-93)
*Mean 6 SD (range).
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patients who did or did not receive interferon treatment
(Table 5).
Correlation of Core Promoter and Precore Mutations With Remis-
sion of Liver Disease After HBeAg Seroconversion. Of the 26
patients who had sustained HBeAg seroconversion, 18 had
elevated alanine transaminase (ALT) levels at presentation;
an additional 7 patients developed intermittent or persis-
tently elevated ALT levels 2 to 50 months before HBeAg
seroconversion. Only 1 patient (patient 2) had persistently
normal ALT levels throughout the study period.
Most (92%) patients had core promoter and/or precore
stop codon mutations after HBeAg seroconversion. Neverthe-
less, 19 (73%) had persistently normal ALT levels during a
follow-up period of 36 6 18 months (range, 13-75 months)
after HBeAg seroconversion (Fig. 2); only 7 (27%) had active
liver disease after HBeAg seroconversion (Table 6). Three
patients continued to have elevated ALT levels for a few
months after HBeAg seroconversion, followed by persistently
normal ALT levels (Fig. 3). Two patients had a transient ALT
flare 18 and 32 months after HBeAg seroconversion. Two
patients had multiple flares in ALT levels despite sustained
HBeAg seroconversion (Fig. 4). There was no correlation
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I 26 C/T yes 11 (42) 2 (8) 3* 11 14 (54) 13 (50)
IA 11 C yes 9 (82) 0 1 0 10 (91) 0
IB 15 T yes 2 (13) 2 (13) 2* 11 4 (27)*† 13 (87)
II 19 C/T no 1 (5) 0 3 2 4 (21) 2 (11)
IIA 11 C no 1 (9) 0 3 0 4 (36) 0
IIB 8 T no 0 0 0 2 0 2 (25)
*One patient had a 21-bp deletion in the core promoter region.
†Three patients had coexistent A1896.




























1 F/31 TA G 210 TA G 146 NA 210 Y
2 M/31 AG G 218 AG G 146 NA Nil Y
3 F/26 TA G 258 TA G* 126 NA 258 Y
4 M/32 TA G† 29 TA G† 126 NA 29 Y
5 M/51 TA G 237 TA G 115 NA 237 Y
6 M/13 AG G 219 TA G 161 NA 124 N
7 F/24 AA G 24 AA G 19 NA 24 N
8 F/35 TA G 250 TA G 12 NA 250 N
9 F/28 AA G 23 AA G 175 NA 23 N
10 F/31 AA G 211 TA G‡ 19 NA 211 N
11 F/31 TA G 21 TA G 126 NA 21 N
Group IB: T1858
12 M/29 TA G 219 TA A 134 212 219 Y
13 M/32 AG G 25 AG A 150 135 Nil Y
14 M/26 AG G 262 AG A 0 216 Nil Y
15 F/27 AG G 222 AG A 15 26 Nil Y
16 F/26 AG G 211 AG G 117 Nil Nil Y
17 M/27 AG G 223 AG A 12 217 Nil Y
18 M/29 AG G 27 AG A 134 117 Nil Y
19 F/32 AG G 248 AG A 129 115 Nil Y
20 F/26 AG A 210 AG A 116 210 Nil Y
21 M/13 AG G 244 Del G 11 Nil Nil N
22 M/30 AG G 0 AG A 151 11 Nil N
23 M/36 AG A 28 AG A 116 28 Nil N
24 M/24 AG G 223 TA A 143 213 213 N
25 F/37 AA§ G 243 AA§ A 115 218 243 N
26 M/35 AG G 24 AG A 168 19 Nil N
NOTE. Time zero 5 time of HBeAg seroconversion.
Abbreviations: CP, core promoter; IFN Rx, interferon treatment (Y 5 yes, N 5 no).
*G-A1898, †precore start codon mutation ATG-AGG; ‡G-A1899; §C-T1766 and T-A1768.
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between the presence of core promoter or precore mutations
and ALT pattern after HBeAg seroconversion (Table 6). All 7
patients with elevated ALT levels after HBeAg seroconverson
were negative for hepatitis C and hepatitis D antibodies and
had detectable serum HBV DNA by hybridization assay.
DISCUSSION
In this study, we found that 92% of Chinese patients in
Hong Kong had mutations in the core promoter and/or
precore regions after sustained HBeAg seroconversion: 42%
had core promoter changes only, 38% had precore changes
only, and 12% had changes in both regions. Similar to other
reports, the most common core promoter mutations in our
patients involved an A-T change at nucleotide 1762 and a
G-A change at nucleotide 1764, while the most common
precore mutation was a G-A change at nucleotide 1896. We
found that the core promoter changes appeared significantly
earlier than the precore changes. In many patients, changes at
both nucleotide positions 1762 and 1764 were already
present at presentation. However, in some patients, progres-
sion from wild-type (AG) to mutant (TA) sequence was
observed during the course of infection. In a few patients, an
intermediate step involving an isolated change at nucleotide
1764 (AA) was noted. None of our patients was found to have
an isolated change at nucleotide 1762 (TG). Despite the early
appearance of the TA changes, several lines of evidence
support a role (albeit small) for the TA changes in the
clearance of HBeAg. In vitro studies showed that the TA
changes can prevent binding of a liver-enriched factor to the
core promoter region, resulting in decreased transcription of
precore RNA and thus secretion of HBeAg.16 We found a
significantly higher prevalence of core promoter changes
among the patients who subsequently cleared HBeAg com-
pared with those who remained HBeAg-positive: 91% versus























27 M/28 TA G TA G 181 0 Y
28 F/13 AG G AG G 173 Nil Y
29 M/14 AG G TA G 193 174 Y
30 M/22 AG G TA G 152 117 Y
31 F/18 AG G AG G 169 Nil Y
32 F/29 AG G TA G 138 19 Y
33 F/18 AG G AG G 146 Nil N
34 M/10 AG G AG G 184 Nil N
35 M/26 AG G AG G 146 Nil N
36 M/17 AG G AG G 175 Nil N
37 M/15 AG G AG G 133 Nil N
Group IIB: T1858 Timing of A1896 (mo)
38 F/19 AG G AG G 172 Nil Y
39 M/18 AG G AG G 184 Nil Y
40 M/40 AG G AG A 186 132 Y
41 M/19 AG G AG G 176 Nil N
42 M/26 AG G AG G 132 Nil N
43 F/23 AG G AG G 133 Nil N
44 M/28 AG G AG G 171 Nil N
45 M/14 AG G AG A 141 138 N
NOTE. Time zero 5 time of first sample.
Abbreviations: CP, core promoter; IFN, interferon treatment (Y 5 yes, N 5 no).
TABLE 5. Effect of Interferon Treatment on the Development of Core
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IA yes 5 0 0
no 6 1 0
IB yes 9 0 7
no 6 2 4
IIA yes 6 3 0
no 5 0 0
IIB yes 3 0 1
no 5 0 1
TABLE 6. Serum Aminotransferase Levels After HBeAg Seroconversion in













TA change only 10 2 8
TA 1 A1896 3 1 2
A1896 only 10 3 7
21-bp deletion in core
promoter region 1 1 0
No change 2 0 2
Total 26 7 (27%)* 19 (73%)
*Three patients had elevated ALT levels during the first 6 months after
HBeAg seroconversion.
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36%. The early emergence of the TA changes compared with
A1896 may be related to the inefficiency of the core promoter
changes in preventing HBeAg production. The TA changes
decrease, but do not completely abolish, HBeAg secretion.16-20
Thus, additional steps such as immune clearance or develop-
ment of other mutations such as A1896 may be needed for
HBeAg clearance. An isolated A1764 change has also been
reported in a small percentage of patients by other investiga-
tors.13 In vitro studies showed that an A1764 change has no
effect on precore RNA transcription, while an isolated T1762
change has a similar suppressive effect on precore RNA
transcription as the combined TA changes.28 It is therefore
not surprising that an A1764 change appeared earlier in the
course of infection.
The overall prevalence of core promoter and/or precore
mutations in our patients was very similar to that reported by
Okamoto et al.,12 but the pattern of changes was markedly
different. In Okamoto’s study, 98% of 57 anti-HBe–positive
patients had core promoter and/or precore changes, 9% had
core promoter changes only, 33% had precore changes only,
and 56% had changes in both regions. Several reasons may
account for the differences in pattern of core promoter and
precore mutations in the two studies. Firstly, all our patients
were observed to seroconvert from HBeAg to anti-HBe, while
Okamoto’s patients were anti-HBe–positive at presentation. A
longer interval between HBeAg seroconversion and testing
may account for a higher prevalence of A1896 in Okamoto’s
patients. A1896 was first detected more than 1 year after
HBeAg seroconversion in 3 (23%) of our patients. It is also
possible that some of Okamoto’s patients were infected with
the precore stop codon mutant ab initio. Secondly, 42% of our
patients were infected with HBV who have C1858. Although
data on the prevalence of HBV with C1858 were not provided
in Okamoto’s article, other reports suggest that HBV geno-
types with C1858 are uncommon in Japan. A higher percent-
age of patients infected with HBV genotypes who have C1858
may account for a lower frequency of A1896 and a higher
frequency of TA changes in our patients (see below).
In accordance with our previous observations,4 we con-
firmed that the precore stop codon mutation (A1896) was
exclusively found in patients infected with HBV who have
T1858. We also found that the core promoter mutations were
significantly more common in patients infected with HBV
who have C1858, which precludes the development of
FIG. 3. Patient 15, who had T1858 in the precore region and normal ALT levels at presentation. Shortly after presentation, this patient developed elevated
ALT levels and precore stop codon mutation (A1896). Serum HBV DNA remained detectable by hybridization assay, and ALT levels continued to be elevated
for 4 months after HBeAg seroconversion, followed by sustained disappearance of serum HBV DNA and normalization of ALT. Broken line, HBV DNA; straight
line, ALT.
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A1896. To our knowledge, this is the first report that suggests
a preferential selection of core promoter mutations in patients
infected with HBV genotypes who have C1858. Although
there have been very little data on the prevalence of core
promoter mutations in countries in which HBV genotypes
with C1858 are common, a study in the United States
reported that 4 (50%) of 8 anti-HBe–positive chronic hepati-
tis B patients had TA changes.29 Further studies are needed to
confirm if core promoter mutations are preferentially selected
in HBV genotypes that cannot develop precore stop codon
mutations and the exact mechanisms by which these muta-
tions are selected. TA changes in the core promoter region
have been reported to be associated with enhanced replica-
tion in in vitro studies,16,17,19 but these findings have been
refuted by other investigators.18 TA changes have also been
postulated to alter the secondary structure of the 38-end of
the pregenomic RNA, thus facilitating DNA minus-strand
translocation to DR1,30 but these effects have not been
proven.
Almost all our patients had core promoter and/or precore
stop codon mutations after HBeAg seroconversion. Neverthe-
less, most had sustained remission of liver disease. Our
experience suggests that HBeAg seroconversion is usually
associated with sustained remission of liver disease, even
when accompanied by the development of core promoter
and/or precore mutations. We acknowledge that our study
population is small and our data may not be applicable to
patients in other geographical regions. However, our data
corroborate previous reports that core promoter and precore
mutations can be detected in anti-HBe–positive carriers with
normal ALT levels. Our findings suggest that core promoter
and/or precore mutations are not necessarily pathogenic and
that additional factors such as mutations in other regions of
the HBV genome, host immune response, or ab initio infec-
tion with the mutants may be important in determining the
course of liver disease in anti-HBe–positive patients.
In summary, we found that the vast majority of our patients
had core promoter and/or precore stop codon mutations after
HBeAg seroconversion. Our data suggest that the core pro-
moter changes are preferentially selected in patients infected
with HBV genotypes who have C1858 that preclude the
development of precore stop codon mutation. The basis for
this selection is not clear, but the core promoter changes may
provide an alternative mechanism for HBeAg clearance in
these patients. Despite the frequent occurrence of core
FIG. 4. Patient 5, who had recurrent flares in ALT and TA changes in the core promoter region before HBeAg serconversion. He had multiple flares in ALT,
accompanied by fluctuations in serum HBV DNA levels after HBeAg seroconversion. Broken line, HBV DNA; straight line, ALT.
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promoter and/or precore mutations, most patients had sus-
tained remission of liver disease after HBeAg seroconversion.
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